trending Market Intelligence /marketintelligence/en/news-insights/trending/7EP2N9CviGnpRXdYFO7LPg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Akebia succeeds in European patent dispute a 2nd time

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Akebia succeeds in European patent dispute a 2nd time

The European Patent Office's Opposition Division revoked another of FibroGen Inc.'s patents related to hypoxia-inducible factor, or HIF, for the treatment of kidney disease.

This is the second of FibroGen's patents related to HIF that was revoked due to a challenge from Akebia Therapeutics Inc.